Application of Nuclear Imaging Probes in PD-L1 Immunotherapy of Tumor

• Published in: Zhongliu fangzhi yanjiu Vol. 48; no. 12; pp. 1123 - 1128
• Main Authors: Yang, Linchao, Li, Wenjie, Chen, Nan
• Format: Journal Article
• Language: Chinese
• Published: Tianjin China Anti-Cancer Association 01-12-2021; Magazine House of Cancer Research on Prevention and Treatment
• Subjects: Biopsy; Heterogeneity; Immunotherapy; Invasiveness; Medical imaging; molecular imaging; Nuclear medicine; Patients; PD-1 protein; pd-l1; PD-L1 protein; Probes; small-molecule inhibitors; Spatial heterogeneity; tumor; Tumors
• ISSN: 1000-8578
• DOI: 10.3971/j.issn.1000-8578.2021.21.0673

Immunotherapy strategies of targeting PD-1 and its ligand PD-L1 are widely administered in varied types of cancer. Patient benefitting from PD-L1 targeted immunotherapy mainly depends on the expression level of PD-L1 in tumor tissues. Currently, the expression level of PD-L1 is primarily detected through the invasive method of biopsy in clinic, which is severely limited by the temporal and spatial heterogeneity of PD-L1 expression. Nuclear medicine probe can realize the noninvasive as well as in vivo detection of PD-L1 at the molecular level, which has important clinical significance for the guidance of patient screening and the prediction of patient's response to immunotherapy. This article reviews PD-L1 targeting nuclear imaging probes and their applications in tumor PD-L1 imaging.